Premium
Evaluation of nevirapine‐switch strategies for HIV treatment
Author(s) -
Cooper CL
Publication year - 2006
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/j.1468-1293.2006.00418.x
Subject(s) - medicine , nevirapine , human immunodeficiency virus (hiv) , virology , intensive care medicine , antiretroviral therapy , viral load
Despite the benefits of protease inhibitor (PI)‐based HIV treatment, issues of tolerability, dosing frequency, pill count and long‐term metabolic complications necessitate evaluation of alternate treatment strategies. The weight of evidence demonstrates that a switch from a PI‐based regimen to one containing nevirapine can be accomplished safely while maintaining virological suppression. There is no immunological cost. There is probably an overall benefit in terms of the metabolic milieu.